MYGN Share Price

Open 19.22 Change Price %
High 19.49 1 Day 0.23 1.20
Low 19.07 1 Week 0.33 1.73
Close 19.38 1 Month 0.13 0.68
Volume 920668 1 Year -16.97 -46.69
52 Week High 39.74
52 Week Low 15.15
MYGN Important Levels
Resistance 2 19.77
Resistance 1 19.61
Pivot 19.31
Support 1 19.15
Support 2 18.99
NASDAQ USA Most Active Stocks
MU 28.43 7.40%
MU 28.43 7.40%
MU 28.43 7.40%
FNFG 10.18 -0.20%
FTR 2.09 7.73%
FTR 2.09 7.73%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
AMCF 0.10 100.00%
VALV 0.04 100.00%
LOCM 0.09 50.00%
BGMD 0.08 33.33%
ESMC 0.12 33.33%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Myriad Genetics, Inc. (NASDAQ: MYGN)

MYGN Technical Analysis 2.5
As on 24th Mar 2017 MYGN Share Price closed @ 19.38 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 23.25 & Strong Buy for SHORT-TERM with Stoploss of 17.60 we also expect STOCK to react on Following IMPORTANT LEVELS.
MYGN Target for March
1st Target up-side 21.83
2nd Target up-side 23.52
3rd Target up-side 25.2
1st Target down-side 17.03
2nd Target down-side 15.34
3rd Target down-side 13.66
MYGN Other Details
Segment EQ
Market Capital 2496680448.00
Sector Services
Industry Research Services
Offical website http://www.myriad.com
MYGN Address
MYGN
320 Wakara Way
Salt Lake City, UT 84108
United States
Phone: 801-584-3600
Fax: 801-584-3640
MYGN Latest News
Interactive Technical Analysis Chart Myriad Genetics, Inc. ( MYGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Myriad Genetics, Inc.
MYGN Business Profile
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).